Skip to main content
SpringerLink
Log in

Die Rolle der Positronenemissionstomographie bei Gliomen

The role of positron emission tomography in gliomas

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Hintergrund

Die Störung der Blut-Hirn-Schranke – gemessen mittels Magnetresonanztomographie – stellt kein zuverlässiges Zeichen von Gliomen dar. Mittels Positronenemissionstomographie (PET) kann ein Aminosäuretransport in die Tumorzellen gemessen werden, unabhängig von der Blut-Hirn-Schranke.

Ziel

Die Arbeit fasst ausgewählte Literatur zur Rolle der PET bei Gliomen zusammen.

Methoden

Anhand von PubMed wurde eine selektive Literaturrecherche durchgeführt.

Ergebnisse

In prägnanter Form erläutert der Artikel die Grundlagen und Durchführung der Aminosäure-PET. Klinische Anwendungen erfassen Tumorausdehnung, Grading und Differenzierung von benignen Befunden, Therapieplanung und -Kontrolle sowie die Differenzierung von Gliomrezidiven und therapiassoziierten Veränderungen.

Schlussfolgerung

Die PET mit radioaktiv markierten Aminosäuren stellt eine wertvolle Zusatzmethode in der Diagnostik und beim Therapiemonitoring von Gliomen dar.

Abstract

Background

Blood-brain barrier disruption as assessed with magnetic resonance imaging is not a reliable sign of gliomas. Positron emission tomography (PET) can be used to measure the transport of amino acids into tumor tissue, independent of the blood-brain barrier.

Objective

This article reviews selected literature about the role of PET in gliomas.

Methods

A search for relevant literature was carried out in PubMed .

Results

In a concise manner this review explains the basic principles and procedures of amino acid PET. Clinical indications cover differentiation of benign findings, glioma delineation, grading, treatment planning and response, as well as differentiation between relapse and treatment-related changes.

Conclusion

PET with radiolabeled amino acids represents a valuable additional tool for the diagnostics and treatment monitoring of gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Albert NL, Weller M, Suchorska B et al (2016) Response assessment in neuro-oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 18:1199–1208

    Article  CAS  Google Scholar 

  2. Albert NL, Winkelmann I, Suchorska B et al (2016) Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans. Eur J Nucl Med Mol Imaging 43:1105–1114

    Article  Google Scholar 

  3. Arbizu J, Tejada S, Marti-Climent JM et al (2012) Quantitative volumetric analysis of gliomas with sequential MRI and (1)(1)C-methionine PET assessment: patterns of integration in therapy planning. Eur J Nucl Med Mol Imaging 39:771–781

    Article  Google Scholar 

  4. Barker FG 2nd, Chang SM, Valk PE et al (1997) 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79:115–126

    Article  CAS  Google Scholar 

  5. Brandsma D, Van Den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22:633–638

    Article  Google Scholar 

  6. Calcagni ML, Galli G, Giordano A et al (2011) Dynamic O‑(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med 36:841–847

    Article  Google Scholar 

  7. Ceccon G, Lohmann P, Stoffels G et al (2017) Dynamic O‑(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro Oncol 19:281–288

    CAS  PubMed  Google Scholar 

  8. Ewelt C, Floeth FW, Felsberg J et al (2011) Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. Clin Neurol Neurosurg 113:541–547

    Article  Google Scholar 

  9. Floeth FW, Pauleit D, Sabel M et al (2006) 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 47:776–782

    CAS  PubMed  Google Scholar 

  10. Galldiks N, Dunkl V, Stoffels G et al (2015) Diagnosis of pseudoprogression in patients with glioblastoma using O‑(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging 42:685–695

    Article  CAS  Google Scholar 

  11. Galldiks N, Langen KJ, Pope WB (2015) From the clinician’s point of view—What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol 17:1434–1444

    Article  CAS  Google Scholar 

  12. Galldiks N, Law I, Pope WB et al (2017) The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin 13:386–394

    Article  Google Scholar 

  13. Galldiks N, Rapp M, Stoffels G et al (2013) Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 40:22–33

    Article  CAS  Google Scholar 

  14. Galldiks N, Stoffels G, Filss C et al (2015) The use of dynamic O‑(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol 17:1293–1300

    Article  CAS  Google Scholar 

  15. Galldiks N, Stoffels G, Ruge MI et al (2013) Role of O‑(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med 54:2046–2054

    Article  CAS  Google Scholar 

  16. Grosu AL, Weber WA (2010) PET for radiation treatment planning of brain tumours. Radiother Oncol 96:325–327

    Article  Google Scholar 

  17. Grosu AL, Weber WA, Riedel E et al (2005) L‑(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 63:64–74

    Article  CAS  Google Scholar 

  18. Heinzel A, Muller D, Langen KJ et al (2013) The use of O‑(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. J Nucl Med 54:1217–1222

    Article  CAS  Google Scholar 

  19. Herholz K, Holzer T, Bauer B et al (1998) 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50:1316–1322

    Article  CAS  Google Scholar 

  20. Hutterer M, Nowosielski M, Putzer D et al (2011) O‑(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 52:856–864

    Article  CAS  Google Scholar 

  21. Jansen EP, Dewit LG, Van Herk M et al (2000) Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol 56:151–156

    Article  CAS  Google Scholar 

  22. Jaymanne DT, Kaushal S, Chan D et al (2018) Utilizing 18F-fluoroethyl-l-tyrosine positron emission tomography in high grade glioma for radiation treatment planning in patients with contraindications to MRI. J Med Imaging Radiat Oncol 62:122–127

    Article  Google Scholar 

  23. Kunz M, Thon N, Eigenbrod S et al (2011) Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 13:307–316

    Article  CAS  Google Scholar 

  24. Langen KJ, Bartenstein P, Boecker H et al (2011) German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids. Nuklearmedizin 50:167–173

    Article  Google Scholar 

  25. Langen KJ, Tatsch K, Grosu AL et al (2008) Diagnostics of cerebral gliomas with radiolabeled amino acids. Dtsch Arztebl Int 105:55–61

    PubMed  PubMed Central  Google Scholar 

  26. Massager N, David P, Goldman S et al (2000) Combined magnetic resonance imaging- and positron emission tomography-guided stereotactic biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients. J Neurosurg 93:951–957

    Article  CAS  Google Scholar 

  27. Oehlke O, Mix M, Graf E et al (2016) Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA)—protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer 16:769

    Article  Google Scholar 

  28. Pauleit D, Floeth F, Hamacher K et al (2005) O‑(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128:678–687

    Article  Google Scholar 

  29. Pauleit D, Stoffels G, Bachofner A et al (2009) Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol 36:779–787

    Article  CAS  Google Scholar 

  30. Piroth MD, Pinkawa M, Holy R et al (2011) Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 80:176–184

    Article  Google Scholar 

  31. Reithmeier T, Lopez WO, Spehl TS et al (2013) Bevacizumab as salvage therapy for progressive brain stem gliomas. Clin Neurol Neurosurg 115:165–169

    Article  CAS  Google Scholar 

  32. Roelcke U, Wyss MT, Nowosielski M et al (2016) Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro Oncol 18:744–751

    Article  CAS  Google Scholar 

  33. Suchorska B, Jansen NL, Linn J et al (2015) Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Baillieres Clin Neurol 84:710–719

    CAS  Google Scholar 

  34. Tanaka Y, Nariai T, Momose T et al (2009) Glioma surgery using a multimodal navigation system with integrated metabolic images. J Neurosurg 110:163–172

    Article  Google Scholar 

  35. Vander Borght T, Asenbaum S, Bartenstein P et al (2006) EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 33:1374–1380

    Article  CAS  Google Scholar 

  36. Wester HJ, Herz M, Weber W et al (1999) Synthesis and radiopharmacology of O‑(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 40:205–212

    CAS  PubMed  Google Scholar 

  37. Wyss M, Hofer S, Bruehlmeier M et al (2009) Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol 95:87–93

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland

    B. Feuerecker, I. Karimov, W. Weber &  I. Yakushev

Authors
  1. B. Feuerecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Karimov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Yakushev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Yakushev.

Ethics declarations

Interessenkonflikt

B. Feuerecker, I. Karimov, W. Weber und I. Yakushev geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Feuerecker, B., Karimov, I., Weber, W. et al. Die Rolle der Positronenemissionstomographie bei Gliomen. Onkologe 25, 31–36 (2019). https://doi.org/10.1007/s00761-018-0503-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-018-0503-z

Schlüsselwörter

Keywords

Search

Navigation